Disrupting LIN28 in atypical teratoid rhabdoid tumors reveals the importance of the mitogen activated protein kinase pathway as a therapeutic targetMelanie Weingart, Eric H. Raabe, Jacquelyn J. Roth et al.|Oncotarget|2014Cited by 85
Interim analysis of LimiTec, a prospective trial of limited-duration teclistamab for relapsed/refractory multiple myelomaBeatrice M. Razzo, Alfred L. Garfall, Sara Whittington et al.|Blood|2025Cited by 6
Disrupting LIN28 in atypical teratoid rhabdoid tumors reveals the importance of the mitogen activated protein kinase pathway as a therapeutic targetRachael Maynard, Sariah J. Allen, Xing gang Mao et al.|UNC Libraries|2020Cited by 0